AIM
MRNA icon

ARK Investment Management’s Moderna MRNA Stock Holding History

ARK Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,163,946
Closed -$77.8M – 188
2024
Q3 		$77.8M Buy
1,163,946
+109,852
+10% +$10.1M 0.71% 31
2024
Q2 		$125M Sell
1,054,094
-163,289
-13% -$20.7M 1.11% 26
2024
Q1 		$130M Buy
1,217,383
+779,980
+178% +$78.6M 0.9% 30
2023
Q4 		$43.5M Buy
437,403
+177,565
+68% +$14.9M 0.26% 52
2023
Q3 		$26.8M Buy
259,838
+116,840
+82% +$13M 0.21% 62
2023
Q2 		$17.4M Sell
142,998
-5,908
-4% -$788K 0.12% 91
2023
Q1 		$22.9M Sell
148,906
-2,038
-1% -$336K 0.16% 68
2022
Q4 		$27.1M Sell
150,944
-12,648
-8% -$2.07M 0.24% 56
2022
Q3 		$19.3M Buy
+163,592
New +$24.8M 0.13% 86

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

ARK Investment Management's MRNA Position: Q4 2024 in Review

ARK Investment Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 1,163,946 shares — an estimated $77.8M sold.

ARK Investment Management first reported a position in MRNA in Q3 2022 and held it in 9 quarters. The position peaked at $130M in Q1 2024. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • ARK Investment Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • ARK Investment Management sold 1,163,946 Moderna shares in Q4 2024, an estimated $77.8M.
  • ARK Investment Management first reported a position in Moderna in Q3 2022 and held it in 9 quarters.
  • ARK Investment Management's Moderna position peaked at $130M in Q1 2024.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on ARK Investment Management's 13F filing for Q4 2024, filed 4 Feb 2025.